• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-09-14

  A 2024 Nature Communications study identifies thioredoxin 1 as a determinant of checkpoint kinase 1 inhibitor response in non-small cell lung cancer. Its central mechanistic insight is that redox recycling of RRM1 sustains ribonucleotide reductase activity and deoxynucleotide availability, providing a rationale for combining CHK1 inhibition with thioredoxin reductase blockade.

• SU5416 (Semaxanib) Angiogenesis Workflows

  2026-09-14

  SU5416 (Semaxanib) combines selective VEGFR2 blockade with a useful AHR-related immune research angle. This practical guide shows how to connect endothelial assays, tumor vascularization studies, and HIF1α-focused metabolic experiments without overinterpreting pathway overlap.

• H 89 2HCl: Reading PKA Signals in Pain

  2026-09-13

  H 89 2HCl enables targeted interrogation of PKA-dependent phosphorylation without directly lowering cAMP. This article connects its pharmacology to trigeminal pain research while emphasizing off-target controls, assay design, and mechanistic interpretation.

• SP600125 in TLR-Driven Inflammation

  2026-09-12

  SP600125 is a JNK inhibitor for dissecting how TLR2/TLR4 signals become inflammatory cytokine outputs. This guide translates the CPSIT_0844 study into a rigorous assay strategy for kinase validation, cytokine expression modulation, and inflammation research.

• LY-411575: Gamma-Secretase Inhibitor Workflows

  2026-09-11

  LY-411575 enables controlled interrogation of amyloid beta processing and Notch-dependent signaling in cell, membrane, and disease-relevant models. This practical guide connects dose-response design, orthogonal readouts, and TNBC immune-microenvironment biology while highlighting selectivity limits and troubleshooting priorities.

• Rhodamine B Workflows for Nanomedicine Imaging

  2026-09-11

  Rhodamine B converts nanoparticle delivery, cell labeling, and tissue-distribution questions into measurable fluorescence readouts. This guide adapts the trypsin-responsive pancreatitis nanomedicine study into practical imaging workflows while separating validated findings from assay-starting recommendations.

• Batimastat (BB-94): Compartment-Aware MMP Assays

  2026-09-10

  Batimastat (BB-94) is a broad-spectrum hydroxamate MMP inhibitor for dissecting extracellular proteolysis. This guide develops a compartment-aware assay strategy linking MMP activity, BDNF processing, neuromuscular junction assembly, and tumor biology without overstating what the reference study directly demonstrated.

• Oteseconazole: From MIC Data to DDI Insight

  2026-09-10

  Oteseconazole (VT-1161) is a selective tetrazole CYP51 inhibitor with potent activity against Candida. This article presents a DDI-aware framework for interpreting susceptibility data, designing translational assays, and evaluating its relevance to recurrent vulvovaginal candidiasis research.

• UBA1, ATG5, and Autophagy in Cardiac Hypertrophy

  2026-09-09

  Lin and colleagues identify UBA1 as a regulator of pathological cardiac hypertrophy that acts by promoting ATG5 ubiquitination and suppressing autophagy. Their combination of pressure-overload modeling, viral gene perturbation, and mechanistic rescue experiments links ubiquitin-dependent ATG5 loss to cardiac remodeling, fibrosis, oxidative stress, and dysfunction.

• DMH1: A Causal Assay Framework for BMP Biology

  2026-09-09

  DMH1 is a selective ALK2 inhibitor for dissecting BMP-dependent cell-state changes. This guide connects pancreatic ductal organoid design with non-small cell lung cancer research while emphasizing controls, assay interpretation, and translational limits.

• ECL Western Blotting Substrate: Practical Guide

  2026-09-08

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for sensitive, nonradioactive protein detection by chemiluminescence in immunoblots. It is intended for HRP-based Western blot assays and should not replace fluorescent or radioisotopic detection reagents.

• SB-505124 Hydrochloride: A Causal Assay Tool

  2026-09-08

  SB-505124 hydrochloride enables reversible dissection of ALK4, ALK5, and ALK7 signaling in fibrosis and cancer mechanobiology. This article shows how to pair pathway inhibition with stiffness, cytoskeletal, and immune-cell assays without confusing correlation with mechanism.

• Dorsomorphin: AMPK, BMP, and Nrf2 Assay Design

  2026-09-07

  Dorsomorphin (Compound C) enables controlled interrogation of AMPK and BMP signaling, but its interpretation changes under viral oxidative stress. This guide develops a redox-aware assay strategy grounded in Nrf2 time-course biology and practical pathway controls.

• Dorsomorphin (Compound C) Research Workflow

  2026-09-07

  Dorsomorphin, also called Compound C, provides a rapid, reversible way to interrogate AMPK-dependent metabolism, autophagy, and differentiation while also exposing BMP pathway biology. This workflow combines phospho-signaling controls, dose optimization, macrophage-inflammation readouts, and safeguards against confounding AMPK-independent BMP effects.

• Crizotinib in Patient-Derived Cancer Assembloids

  2026-09-05

  A translational framework for using Crizotinib hydrochloride to connect ALK, c-Met, and ROS1 pathway biology with patient-derived gastric cancer assembloids, stromal modulation, and resistance-aware drug testing.

8041 records 1/537 page Next 12345 下5页 Last page